Anemia and chronic kidney disease: Making sense of the recent trials

Reviews on Recent Clinical Trials

Volumn 7, Issue 3, 2012, Pages 187-196

  Ramanath, Vinayak ^a   Gupta, Diptesh ^a   Jain, Juhi ^a   Chaudhary, Kunal ^b,c   Nistala, Ravi ^a,c  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Anemia; Chronic Kidney Disease; ESA; Iron

Indexed keywords

ANTINEOPLASTIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR; ZIDOVUDINE;

ANEMIA; ARTERY THROMBOSIS; BLOOD CELL COUNT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIAGNOSTIC PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETICULOCYTE COUNT; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANEMIA; CARDIOVASCULAR DISEASES; ERYTHROPOIETIN; HEMATINICS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; RISK FACTORS; UNITED STATES;

EID: 84866712349     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488712802281222     Document Type: Review

References (88)

1. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005; 16(6): 1803-10.
2. Barrett BJ, Fenton SS, Ferguson B, et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 1999; 10 (Suppl 13): S292-6.
3. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47(5 Suppl 3): S16-85.
4. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12(11): 2465-73.
5. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44(1): 94-111.
6. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355(20): 2085-98.
7. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355(20): 2071-84.
8. Roy CN, Carlson EJ, Anderson EL, et al. Interactions of the ectodomain of HFE with the transferrin receptor are critical for iron homeostasis in cells. FEBS Lett 2000; 484(3): 271-4.
9. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341(26): 1986-95.
10. Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388(6641): 482-8.
11. Riedel HD, Remus AJ, Fitscher BA, Stremmel W. Characterization and partial purification of a ferrireductase from human duodenal microvillus membranes. Biochem J 1995; 309 (Pt 3): 745-8.
12. Roy CN, Enns CA. Iron homeostasis: new tales from the crypt. Blood 2000; 96(13): 4020-7.
13. Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev 2010; 24(1): 39-47.
14. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102(3): 783-8.
15. Atanasiu V, Manolescu B, Stoian I. Hepcidin--central regulator of iron metabolism. Eur J Haematol 2007; 78(1): 1-10.
16. Desforges JF. Anemia in uremia. Arch Intern Med 1970; 126(5): 808-11.
17. Erslev AJ. Anemia of chronic renal disease. Arch Intern Med 1970; 126(5): 774-80.
18. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 1979; 54(4): 877-84.
19. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24(3): 495-9.
20. Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med 1999; 16(10): 813-9.
21. Ifudu O. Relative contribution of secondary hyperparathyroidism to anemia in end-stage renal disease. Dialysis Transplant 2002; 31(4): 247-9.
22. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38(4): 803-12.
23. Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, et al. Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol 2006; 85(2): 79-85.
24. Besarab A, Levin A. Defining a renal anemia management period. Am J Kidney Dis 2000; 36(6 Suppl 3): S13-23.
25. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 1984; 25(2): 437-44.
26. Ibrahim FF, Ghannam MM, Ali FM. Effect of dialysis on erythrocyte membrane of chronically hemodialyzed patients. Ren Fail 2002; 24(6): 779-90.
27. Chaplin H, Jr., Mollison PL. Red cell life-span in nephritis and in hepatic cirrhosis. Clin Sci (Lond) 1953; 12(4): 351-60.
28. Sotirakopoulos N, Tsitsios T, Stambolidou M, et al. The red blood cell deformability in patients suffering from end stage renal failure on hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail 2004; 26(2): 179-83.
29. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999; 94(8): 2569-74.
30. Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int Suppl 2001; 78: S67-72.
31. Dunn CD, Trent D. The effect of parathyroid hormone on erythropoiesis in serum-free cultures of fetal mouse liver cells. Proc Soc Exp Biol Med 1981; 166(4): 556-61.
32. Meytes D, Bogin E, Ma A, Dukes PP, Massry SG. Effect of parathyroid hormone on erythropoiesis. J Clin Invest 1981; 67(5): 1263-9.
33. Komatsuda A, Hirokawa M, Haseyama T, et al. Human parathyroid hormone does not influence human erythropoiesis in vitro. Nephrol Dial Transplant 1998; 13(8): 2088-91.
34. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Schohn D, Chuet C. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dialysis Transplant 1997; 12(3): 514-8.
35. Argiles A, Lorho R, Mourad G, Mion CM. High-dose alfacalcidol for anaemia in dialysis. Lancet 1993; 342(8867): 378-9.
36. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1 Suppl 1: S4-8.
37. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47(5 Suppl 3): S11-145.
38. Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986; 145(5): 657-63.
39. Lok CN, Loh TT. Regulation of transferrin function and expression: review and update. Biol Signals Recept 1998; 7(3): 157-78.
40. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352(10): 1011-23.
41. Fishbane S, Galgano C, Langley RC, Jr., Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997; 52(1): 217-22.
42. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol 2008; 83(4): 307-10.
43. Schaefer RM, Schaefer L. Hypochromic red blood cells and reticulocytes. Kidney Int Suppl 1999; 69: S44-8.
44. Sawada K, Krantz SB, Dai CH, et al. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors. J Cell Physiol 1990; 142(2): 219-30.
45. Sawyer ST, Penta K. Erythropoietin cell biology. Hematol Oncol Clin North Am 1994; 8(5): 895-911.
46. Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer Adherence 2008; 2: 195-200.
47. Locatelli F, Del Vecchio L. Erythropoiesis-stimulating agents in renal medicine. Oncologist 2011;16 Suppl 3: 19-24.
48. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008; 3(1): 200-7.
49. Tanaka T, Nangaku M. Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD. J Pharmacol Sci 2009; 109(1): 24-31.
50. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002; 16(10): 1151-62.
51. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339(9): 578-83.
52. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005; 64(2): 113-23.
53. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005; 63(5): 327-34.
54. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368(9539): 947-53.
55. Locatelli F, Villa G, de Francisco AL, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007; 23(5): 969-79.
56. Levin NW, Fishbane S, Canedo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370(9596): 1415-21.
57. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3(2): 337-47.
58. Kimel M, Leidy NK, Mannix S, Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health 2008; 11(1): 57-75.
59. Nissenson AR. Epoetin and cognitive function. Am J Kidney Dis 1992; 20(1 Suppl 1): 21-4.
60. Nissenson AR. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 1989; 9(1 Suppl 2): 25-31.
61. Wish J, Schulman K, Law A, Nassar G. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res 2009; 32(2): 110-8.
62. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail 2000; 22(4): 435-44.
63. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58(3): 1325-35.
64. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18(2): 353-61.
65. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66(2): 753-60.
66. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15(1): 148-56.
67. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46(5): 799-811.
68. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16(7): 2180-9.
69. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006; 47(5): 738-50.
70. Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007; 22(3): 784-93.
71. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49(2): 194-207.
72. Cianciaruso B, Ravani P, Barrett BJ, Levin A. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. J Nephrol 2008; 21(6): 861-70.
73. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361(21): 2019-32.
74. Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010; 25(12): 4009-17.
75. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18(1): 141-6.
76. Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 2005; 68(2): 788-95.
77. Frank H, Heusser K, Hoffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int 2004; 66(2): 832-40.
78. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77(2): 176-85.
79. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153(1): 23-33.
80. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50(3): 471-530.
81. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74(6): 791-8.
82. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363(12): 1146-55.
83. Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? Kidney Int 2007; 72(7): 806-13.
84. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003; 29(5): 451-8.
85. Coleman TR, Westenfelder C, Togel FE, et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A 2006; 103(15): 5965-70.
86. Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009; 24(4): 1082-8.
87. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339(9): 584-90.
88. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2(6): 1274-82.